Group Differences of Multiregion Glutamate Concentration in Clinical High Risk and Schizophrenia
Open Access
- 10 July 2026
- journal article
- research article
- Published by Wiley in European Journal of Neuroscience
- Vol. 64 (1) , e70626
Abstract
Glutamatergic changes are one of the characteristic features of psychotic disorders, with changes reported in their clinical high‐risk states (CHR), first episode psychosis (FEP), and schizophrenia. Despite the abundance of literature using proton magnetic resonance ( 1 H‐MRS) to quantify glutamate, the general pattern of changes across different brain regions is not well studied. We investigated the presence of diagnosis group effects on glutamate concentrations in 99 participants in the left dorsal lateral prefrontal cortex, anterior cingulate cortex, associative striatum, and hippocampus using 1 H‐MRS in individuals with CHR ( n = 31), schizophrenia spectrum psychotic disorder individuals (SCZ) with minimal antipsychotic exposure ( n = 30), and healthy controls ( n = 38). 1 H‐MRS data were normalized against white matter, gray matter, and cerebrospinal fluid fractions within regions of interest (ROI) to quantify local glutamate concentration. Our results showed no significant group differences in glutamate concentration across the four ROIs. Exploratory analyses showed a significant relationship between region and positive symptom severity on glutamate concentration. Post hoc regression analyses revealed that higher positive symptom severity was significantly associated with higher hippocampal glutamate concentrations. We conclude that glutamate concentrations may be related to positive symptoms.Keywords
Funding Information
- Canada Foundation for Innovation (260879)
This publication has 42 references indexed in Scilit:
- Hippocampal dysregulation of dopamine system function and the pathophysiology of schizophreniaTrends in Pharmacological Sciences, 2011
- Higher Levels of Glutamate in the Associative-Striatum of Subjects with Prodromal Symptoms of Schizophrenia and Patients with First-Episode PsychosisNeuropsychopharmacology, 2011
- Frontolimbic glutamate alterations in first episode schizophrenia: Evidence from a magnetic resonance spectroscopy studyThe World Journal of Biological Psychiatry, 2008
- Increased Prefrontal and Hippocampal Glutamate Concentration in Schizophrenia: Evidence from a Magnetic Resonance Spectroscopy StudyBiological Psychiatry, 2005
- Long-Term Diagnostic Stability and Outcome in Recent First-Episode Cohort Studies of SchizophreniaSchizophrenia Bulletin, 2005
- Age-related glutamate and glutamine concentration changes in normal human brain: 1H MR spectroscopy study at 4 TNeurobiology of Aging, 2005
- NMDA receptor antagonist effects, cortical glutamatergic function, and schizophrenia: toward a paradigm shift in medication developmentPsychopharmacology, 2003
- Prodromal Assessment With the Structured Interview for Prodromal Syndromes and the Scale of Prodromal Symptoms: Predictive Validity, Interrater Reliability, and Training to ReliabilitySchizophrenia Bulletin, 2003
- The MacCAT-T: a clinical tool to assess patients' capacities to make treatment decisionsPsychiatric Services, 1997
- The Positive and Negative Syndrome Scale (PANSS) for SchizophreniaSchizophrenia Bulletin, 1987